Welcome to our dedicated page for BIO-RAD LABORATORIES SEC filings (Ticker: BIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BIO-RAD LABORATORIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BIO-RAD LABORATORIES's regulatory disclosures and financial reporting.
Bio-Rad Laboratories reported results of its April 21, 2026 annual meeting. Stockholders approved an amended 2017 Incentive Award Plan that increases the shares of common stock reserved for issuance by 335,000 and extends the plan’s expiration to March 18, 2036.
All nominated directors were elected by the required majorities, KPMG LLP was ratified as independent auditor for the year ending December 31, 2026, and executive compensation received majority support in a non-binding advisory vote. A stockholder proposal regarding the company’s dual class capital structure did not receive the required majority approval.
Hinckley Greg K reported acquisition or exercise transactions in this Form 4 filing.
Bio-Rad Laboratories director Greg K. Hinckley increased his direct equity stake through routine equity compensation. On April 21, 2026, 407 restricted stock units vested and were settled into 407 shares of Bio-Rad Class A common stock. Following this settlement, Hinckley directly held 1,215 shares of Class A common stock.
On the same date, he received a new grant of 369 restricted stock units, each representing a contingent right to one share of Bio-Rad Class A common stock. These units will vest 100% on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders.
Bio-Rad Laboratories director Melinda Litherland reported routine equity compensation activity. She exercised 407 restricted stock units into 407 shares of Bio-Rad Class A common stock, bringing her direct common stock holdings to 715 shares.
On the same date, she received a new grant of 369 restricted stock units, each representing a right to one share of Class A common stock. These new units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company’s next annual meeting of stockholders, aligning her compensation with future company performance and governance milestones.
Bio-Rad Laboratories director Jeffrey L. Edwards exercised restricted stock units into Bio-Rad Class A common shares and received a new equity award. He acquired 407 shares of Bio-Rad A Common Stock upon vesting of restricted stock units, bringing his direct holdings to 715 shares.
At the same time, 407 Restricted Stock Units were fully converted, leaving no remaining units from that grant. Edwards was also granted 369 new Restricted Stock Units, each representing a contingent right to receive one share of Bio-Rad Class A common stock, vesting 100% on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders.
BIO-RAD LABORATORIES, INC. director Arnold A. Pinkston reported routine equity compensation activity. He acquired 407 shares of Bio-Rad Class A common stock upon vesting of restricted stock units, bringing his direct common stock holdings to 715 shares after the transaction.
The filing also shows 407 restricted stock units were fully settled, reducing that RSU position to zero. In addition, he received a new grant of 369 restricted stock units, each representing one share of Class A common stock, which will vest 100% on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders.
The Vanguard Group filed an amended Schedule 13G reporting that it currently beneficially owns 0 shares (0%) of Bio-Rad Laboratories Inc. The filing explains that on January 12, 2026 Vanguard completed an internal realignment and began reporting certain subsidiaries' holdings separately, in accordance with SEC Release No. 34-39538 (January 12, 1998). The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Bio-Rad Laboratories is asking stockholders to vote at its 2026 annual meeting on director elections, auditor ratification, executive pay, an amended long‑term incentive plan, and a stockholder proposal on its dual‑class structure. The meeting will be held on April 21, 2026 at company headquarters in Hercules, California.
Holders of Class A and Class B shares vote separately to elect two and four directors, respectively, while most other items are decided by a majority of combined voting power present. The board recommends voting for all company proposals, including the advisory say‑on‑pay and the amended 2017 Incentive Award Plan, and against the stockholder proposal seeking changes to the dual‑class capital structure.
The amended equity plan would add to the share reserve and extend the plan’s term to March 18, 2036, with features such as minimum one‑year vesting (with limited exceptions), clawback applicability, no dividends on unvested awards, and a per‑director annual award cap. KPMG LLP is proposed to continue as independent auditor, with 2025 audit fees of $6,192,000 and other 2025 fees of $244,000.
Bio-Rad Laboratories, Inc. filed an update on its investment in Sartorius AG, sharing Sartorius’ latest full-year 2025 financial figures that Sartorius disclosed on February 16, 2026. The data come directly from Sartorius’ audited consolidated financial statements prepared under IFRS.
For the year ended December 31, 2025, Sartorius reported sales revenue of €3,538.1 million, gross profit of €1,636.7 million, earnings before interest and taxes (EBIT) of €542.6 million and net profit of €230.4 million. Cash flow from operating activities was €837.0 million, while cash flows from investing and financing activities were negative €513.7 million and €591.4 million, respectively. As of December 31, 2025, Sartorius reported current assets of €1,766.2 million, non-current assets of €7,951.1 million, current liabilities of €1,967.4 million, non-current liabilities of €3,882.6 million and equity of €3,867.2 million.
Bio-Rad Laboratories, Inc. files its annual report describing a diversified life science and clinical diagnostics business with global reach. For the year ended December 31, 2025, the Life Science segment and Clinical Diagnostics segment generated approximately 40% and 60% of consolidated net sales, and about 40% of sales came from the U.S., with 60% from international markets.
The company highlights extensive regulatory, reimbursement, and cybersecurity exposure, along with supply chain and macroeconomic risks. Bio-Rad reports approximately 7,450 employees worldwide and continues to invest heavily in research and development. The report also details a significant strategic stake in Sartorius AG, with a fair value of $5,669.2 million as of December 31, 2025, and notes outstanding long-term debt of approximately $1.2 billion in senior notes and remaining authorization of $284.6 million under a share repurchase program.